Frazier Life Sciences
QuietFiled to raiseSeattle, WABiotech & pharma, Medical devicesLast fund filed 2025
3 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Frazier Life Sciences XIIFiled to raise in 2025, with no closing reported yet. | 2025 | Indefinite | $0 | 0 |
| Frazier Life Sciences Public Fund | July 2024 | Indefinite | $476M | 142 |
| Frazier Life Sciences XI | March 2022 | $960M | $960M | 98 |
| Frazier Life Sciences XFiled to raise in 2019, with no closing reported yet. | 2019 | $617M | $0 | 0 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
5 partners are named across this firm’s filings, 3 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Daniel EstesNot on the current fund | Quiet | Biotech & pharma | 7 |
Categories of Frazier Life Sciences’s own portfolio companies, based on 33 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Frazier Life Sciences’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Vivo Capital | 3 | Nexcida Therapeutics, Outpost Medicine, ProNAi Therapeutics |
| Advent Life Sciences | 2 | Iterum Therapeutics Bermuda, Iterum Therapeutics plc |
| Bain Capital Life Sciences | 2 | Aptinyx, Arcutis Biotherapeutics |
| Frazier Life Sciences IX |
| October 2017 |
| $419M |
| $419M |
| 55 |
| Frazier Life Sciences VIII | October 2015 | $262M | $262M | 46 |
| 0 |
| James TopperNot on the current fund | Quiet | Biotech & pharma, Medical devices | 13 | 0 |
| Jamie Brush | Quiet | None listed | 0 | 0 |
| Jamie Topper | Quiet | None listed | 0 | 0 |
| Patrick Heron | Quiet | Biotech & pharma | 15 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
| 2 |
| Alcresta Therapeutics, Allena Pharmaceuticals |
| Longitude Capital | 2 | Aptinyx, SutroVax |
| NEA | 2 | MBX Biosciences, Mirum Pharmaceuticals |
| Sofinnova Venture Partners | 2 | Alcresta Therapeutics, Iterum Therapeutics Bermuda |
| Tapestry VC | 2 | Iterum Therapeutics Bermuda, Iterum Therapeutics plc |
| TCG Crossover | 2 | Nexcida Therapeutics, Outpost Medicine |
| 270 Healthcare Growth | 1 | Enlaza Therapeutics |
| Abingworth Bioventures | 1 | Enlaza Therapeutics |
| Aditum Bio | 1 | ALPINE IMMUNE SCIENCES |
| Aisling Capital | 1 | K2 THERAPEUTICS |
| Excelerate Health Ventures | 1 | Radionetics Oncology |
| Healthquest Partners | 1 | Alcresta Therapeutics |
A shared board seat: a company where filings name a Frazier Life Sciences partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.